X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs JUBILANT LIFE SCIENCES - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB JUBILANT LIFE SCIENCES DR. REDDYS LAB/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 27.9 20.2 138.3% View Chart
P/BV x 2.9 4.3 67.0% View Chart
Dividend Yield % 1.0 0.4 232.3%  

Financials

 DR. REDDYS LAB   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
DR. REDDYS LAB/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs4,383187 2,346.4%   
Low Rs2,75065 4,224.3%   
Sales per share (Unadj.) Rs920.1364.3 252.5%  
Earnings per share (Unadj.) Rs126.16.8 1,842.0%  
Cash flow per share (Unadj.) Rs183.024.5 746.9%  
Dividends per share (Unadj.) Rs20.003.00 666.7%  
Dividend yield (eoy) %0.62.4 23.5%  
Book value per share (Unadj.) Rs685.8164.9 415.9%  
Shares outstanding (eoy) m170.61159.28 107.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.90.3 1,121.3%   
Avg P/E ratio x28.318.4 153.7%  
P/CF ratio (eoy) x19.55.1 379.1%  
Price / Book Value ratio x5.20.8 680.8%  
Dividend payout %15.943.8 36.2%   
Avg Mkt Cap Rs m608,48120,061 3,033.1%   
No. of employees `00021.76.2 350.3%   
Total wages/salary Rs m31,87411,052 288.4%   
Avg. sales/employee Rs Th7,244.49,383.0 77.2%   
Avg. wages/employee Rs Th1,470.91,786.9 82.3%   
Avg. net profit/employee Rs Th992.8176.3 563.2%   
INCOME DATA
Net Sales Rs m156,97858,034 270.5%  
Other income Rs m2,693191 1,412.9%   
Total revenues Rs m159,67158,224 274.2%   
Gross profit Rs m34,5875,786 597.7%  
Depreciation Rs m9,7052,812 345.2%   
Interest Rs m8243,237 25.5%   
Profit before tax Rs m26,751-72 -37,102.6%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m5,237696 752.0%   
Profit after tax Rs m21,5141,090 1,973.0%  
Gross profit margin %22.010.0 221.0%  
Effective tax rate %19.6-965.9 -2.0%   
Net profit margin %13.71.9 729.4%  
BALANCE SHEET DATA
Current assets Rs m118,20129,280 403.7%   
Current liabilities Rs m68,36838,912 175.7%   
Net working cap to sales %31.7-16.6 -191.3%  
Current ratio x1.70.8 229.8%  
Inventory Days Days6084 71.1%  
Debtors Days Days9751 191.1%  
Net fixed assets Rs m72,26555,712 129.7%   
Share capital Rs m853155 552.1%   
"Free" reserves Rs m111,54820,968 532.0%   
Net worth Rs m117,00926,265 445.5%   
Long term debt Rs m10,69017,169 62.3%   
Total assets Rs m200,10488,606 225.8%  
Interest coverage x33.51.0 3,422.7%   
Debt to equity ratio x0.10.7 14.0%  
Sales to assets ratio x0.80.7 119.8%   
Return on assets %11.24.9 228.6%  
Return on equity %18.44.2 442.9%  
Return on capital %21.611.6 186.7%  
Exports to sales %46.337.8 122.4%   
Imports to sales %9.016.5 54.3%   
Exports (fob) Rs m72,61821,933 331.1%   
Imports (cif) Rs m14,0509,567 146.9%   
Fx inflow Rs m75,40522,004 342.7%   
Fx outflow Rs m27,11511,749 230.8%   
Net fx Rs m48,29010,255 470.9%   
CASH FLOW
From Operations Rs m40,4768,026 504.3%  
From Investments Rs m-19,421-1,744 1,113.5%  
From Financial Activity Rs m-17,009-4,447 382.4%  
Net Cashflow Rs m4,0461,834 220.6%  

Share Holding

Indian Promoters % 25.5 45.6 55.9%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 5.4 8.7 62.1%  
FIIs % 35.3 21.2 166.5%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 21.1 72.5%  
Shareholders   75,885 23,815 318.6%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Realty & Pharma Stocks Lead(09:30 am)

Asian stock indices are trading mixed today. The Shanghai Composite is lower by 0.29% while the Hang Seng is even. The Nikkei 225 is trading higher by 0.46%.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 23, 2017 10:44 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS